It is abundantly clear from both experimental observations and clinical experience, that interactions between the liver and the lungs can play a critical role in the initiation and outcome of lung inflammation. We propose a Program Project consisting of four inter-related projects and three core areas to investigate mechanisms of interactions between the liver and the lungs in acute lung injury syndromes. The underlying theme, addressed in different by each of the projects, is that hepatic injury, whether resulting from endotoxemia, direct trauma or drug injury, can signal an inflammatory response in the lungs that may eventuate in acute lung injury and that eicosanoids play a critical role in modulating that process. Pro-inflammatory cytokines, including tumor necrosis factor alpha, produced in the liver, comprise the liver inflammatory signal. Activation of two transcription factors, nuclear factor kappa B (NFkB) and CCAAT enhancer binding protein beta (C/EBPbeta a.k.a. NF-IL6) is critical to the response in the lungs and in the liver and the course of the response of the lungs to liver injury is determined by the pattern of activation of these two factors. Oxidant stress is common to many causes of hepatic injury and abnormalities in function of the hepatic urea cycle exaggerate oxidant stress resulting in enhanced activation of transcription factors and thus cytokine release, amplifying the inflammatory signal to the lungs. The program forms a structural basis for enhancing previous and existing collaborations among investigators from Pulmonary Medicine, Surgery, Pediatrics, Pharmacology, Biochemistry, Microbiology and Immunology and Molecular Physiology and Biophysics. The program as a whole will integrate the pathophysiology of lung injury with biochemical cellular and molecular mechanisms of liver-lung relationships that contribute to or moderate the inflammatory response. Experimental approaches include whole animal physiologic preparations as well as numerous genetically altered mouse models and bone marrow and hepatocyte transplantation technology as experimental tools. The proposal promises to obtain new information related to mechanisms of lung injury which will be clinically relevant by providing rationales for new preventive or therapeutic strategies as well as the ability to identity at risk individuals The proposal results from the conviction by the involved investigators that the common themes, complementary expertise and unique technologies assembled into a coordinated program will be more creative, more productive and more likely ti advance understanding of the pathogenesis and potential therapy of inflammatory lung disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL066196-05
Application #
6998889
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Harabin, Andrea L
Project Start
2002-01-01
Project End
2007-11-30
Budget Start
2005-12-01
Budget End
2007-11-30
Support Year
5
Fiscal Year
2006
Total Cost
$1,771,508
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Tiriveedhi, Venkataswarup; Upadhya, Gundumi A; Busch, Rebecca A et al. (2014) Protective role of bortezomib in steatotic liver ischemia/reperfusion injury through abrogation of MMP activation and YKL-40 expression. Transpl Immunol 30:93-8
Ramachandran, Sabarinathan; Liaw, Jane M; Jia, Jianluo et al. (2012) Ischemia-reperfusion injury in rat steatotic liver is dependent on NF?B P65 activation. Transpl Immunol 26:201-6
Tiriveedhi, Venkataswarup; Conzen, Kendra D; Liaw-Conlin, Jane et al. (2012) The role of molecular chaperonins in warm ischemia and reperfusion injury in the steatotic liver: a proteomic study. BMC Biochem 13:17
Lee, Hye Jeong; Joo, Myungsoo; Abdolrasulnia, Rasul et al. (2010) Peptidylarginine deiminase 2 suppresses inhibitory {kappa}B kinase activity in lipopolysaccharide-stimulated RAW 264.7 macrophages. J Biol Chem 285:39655-62
Joo, Myungsoo; Kwon, Minjae; Cho, Yong-Jig et al. (2009) Lipopolysaccharide-dependent interaction between PU.1 and c-Jun determines production of lipocalin-type prostaglandin D synthase and prostaglandin D2 in macrophages. Am J Physiol Lung Cell Mol Physiol 296:L771-9
Han, Wei; Joo, Myungsoo; Everhart, M Brett et al. (2009) Myeloid cells control termination of lung inflammation through the NF-kappaB pathway. Am J Physiol Lung Cell Mol Physiol 296:L320-7
Cao, Hongmei; Xiao, Lei; Park, Gyeyoung et al. (2008) An improved LC-MS/MS method for the quantification of prostaglandins E(2) and D(2) production in biological fluids. Anal Biochem 372:41-51
Stathopoulos, Georgios T; Sherrill, Taylor P; Han, Wei et al. (2008) Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol Cancer Res 6:364-71
Stathopoulos, Georgios T; Sherrill, Taylor P; Han, Wei et al. (2008) Use of bioluminescent imaging to investigate the role of nuclear factor-kappaBeta in experimental non-small cell lung cancer metastasis. Clin Exp Metastasis 25:43-51
Joo, Myungsoo; Kwon, Minjae; Azim, Anser C et al. (2008) Genetic determination of the role of PU.1 in macrophage gene expression. Biochem Biophys Res Commun 372:97-102

Showing the most recent 10 out of 46 publications